全球 3D 列印藥物市場規模、佔有率、成長分析，依技術類型（噴墨列印、熔融沈積建模）、依應用（骨科、神經科）- 2024-2031 年產業預測

Global 3D Printed Drugs Market Size, Share, Growth Analysis, By Technology Type(Inkjet Printing, Fused Deposition Modeling), By Application(Orthopaedic, Neurology) - Industry Forecast 2024-2031

出版日期: 2024年04月06日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022 年，全球 3D 列印藥物市場規模為 8,491 萬美元，預計將從 2023 年的 9,850 萬美元成長到 2031 年的 3.2291 億美元，預測期內（2024-2031 年）複合年成長率為 16%。

在製藥業中，3D列印藥品市場正在全球快速擴張。越來越多的藥物配方可以使用3D列印技術來客製化，這可以提高藥物療效、減少副作用並提供個人化劑量。 3D 列印的方法是沉積連續的材料層來創建3D物體。在藥物生產中，這需要將精確的藥物劑量列印到基材上。市場以北美、歐洲和亞太地區為主。市場的擴張可歸因於對定製藥物的需求不斷成長、技術改進以及 3D 列印提供準確劑量和盡量減少負面影響的能力。 3D 列印藥物市場旨在提供一種新穎且富有創意的藥物生產方法，以改善患者的治療效果並降低醫療成本。由於在藥物製造中使用 3D 列印技術，藥物可以依需生產，從而減少浪費並提高設計自由度。降低醫療成本的需求、技術改進、3D 列印提供精確劑量和防止副作用的潛力以及對個體化藥物日益成長的需求是推動 3D 列印藥物市場成長的主要因素。 3D列印技術成本高以及3D列印藥品難以獲得監管機構批准是阻礙3D列印藥品產業發展的主要問題。 3D列印藥物市場存在一些障礙，例如需要更多的研究和開發以確保這些產品的功效和安全性、標準化3D列印程序的要求以及可能出現的智慧財產權問題。新穎和創造性藥物組合物的創造、市場向新地理區域的成長以及 3D 列印徹底改變個人化醫療和藥物輸送的可能性都是 3D 列印藥品市場的機會。對於製藥公司來說，在藥品製造中使用 3D 列印技術可以開闢新的收入來源。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名企業比較
2021 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率（%），2021年

主要公司簡介

Aprecia Pharmaceuticals - (US)
FabRx - (UK)
GlaxoSmithKline - (UK)
Pfizer - (US)
Merck - (US)
Sanofi - (France)
3D Systems - (US)
BASF - (Germany)
Teva Pharmaceuticals - (Israel)
Novartis - (Switzerland)
Roche - (Switzerland)
Catalent - (US)
Johnson & Johnson - (US)
Vertex Pharmaceuticals - (US)
Boehringer Ingelheim - (Germany)
Siemens Healthineers - (Germany)
Sandoz International - (Germany)
BioBots - (US)
Apium Additive Technologies - (Germany)
Boston Micro Fabrication - (US)

簡介目錄

Product Code: SQMIG35I2140

Global 3D Printed Drugs Market size was valued at USD 84.91 Million in 2022 and is poised to grow from USD 98.5 Million in 2023 to USD 322.91 Million by 2031, at a CAGR of 16% during the forecast period (2024-2031).

Within the pharmaceutical industry, the 3D printed drug market is expanding quickly on a global scale. A growing number of pharmaceutical formulations can be made to order using 3D printing technology, which can increase medication efficacy, lessen side effects, and offer individualized dosage. The method of 3D printing is depositing consecutive layers of material to create a three-dimensional object. In the context of drug production, this entails printing exact medication dosages onto a substrate. The market is dominated by North America, Europe, and Asia Pacific. The market's expansion can be ascribed to the rising need for customized medications, technological improvements, and 3D printing's capacity to deliver accurate dosage and minimize negative effects. The market for 3D printed medications aims to offer a fresh and inventive approach to producing medications that might enhance patient outcomes and lower medical expenses. Drugs may be produced on demand, with less waste and more design freedom thanks to the use of 3D printing technology in medication manufacturing. The need to lower healthcare costs, technological improvements, the potential of 3D printing to deliver exact dosing and prevent side effects, and the growing need for individualized medications are the main factors propelling the growth of the 3D printed drugs market. The high cost of 3D printing technology and the difficulties in getting 3D printed drug approval from regulatory bodies are the main issues impeding the growth of the 3D printed drug industry. The market for 3D printed medications has several obstacles, such as the requirement for more research and development to guarantee the efficacy and safety of these products, the requirement to standardize 3D printing procedures, and the possibility of intellectual property issues. The creation of novel and inventive medication compositions, the market's growth into new geographic areas, and the possibility for 3D printing to revolutionize personalized medicine and drug delivery are among the opportunities in the 3D printed pharmaceuticals market. For pharmaceutical businesses, the use of 3D printing technology in drug manufacture could open up new revenue sources.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global 3D Printed Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global 3D Printed Drugs Market Segmental Analysis

The global 3D printed drugs market is segmented on the basis of product, application, and region. By technology, the market is segmented into inkjet printing, fused deposition modeling, stereolithography, zipdose technology. By application, the market is segmented into orthopedic, neurology, dental, others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global 3D Printed Drugs Market

The global market for 3D printed drugs is mostly driven by the rising need for customized medications. Medications that are customized for each patient based on their genetics, lifestyle, and surroundings are known as personalized medicines. Compared to conventional medications, these medications provide a number of benefits, including as greater efficacy, fewer side effects, and higher patient compliance. 3D printing technology is perfect for producing tailored pharmaceuticals since it allows the fabrication of unique drug compositions with accurate dosing and drug release characteristics. Pharmaceutical businesses can now produce medications with distinctive formulas and geometries that are not possible with conventional manufacturing techniques thanks to 3D printing. The necessity for focused drug administration and the growing incidence of chronic diseases are driving up demand for personalized medicines. Long-term care is necessary for chronic conditions like cancer, diabetes, and cardiovascular disease, and individualized medication can enhance patient outcomes and quality of life. Targeted medication administration can also lower the dosage needed, which will lessen adverse effects and increase patient compliance. The market for 3D printed medications is anticipated to expand rapidly in the upcoming years. Global demand for 3D printed drugs is predicted to rise quickly due to the growing need for customized medications and technological developments in this field.

Restraints in the Global 3D Printed Drugs Market

The substantial upfront costs associated with 3D printing hardware, software, and supplies make it challenging for small and medium-sized pharmaceutical enterprises to implement the technology. Because of the high cost of materials and the length of time needed for production, 3D printed medications may have a greater cost per unit than conventional pharmaceuticals. This may result in patients finding 3D printed medications less affordable, which would lower demand for the goods. The regulatory landscape surrounding 3D printed medications is continuously evolving, and obtaining regulatory approval can be a costly and time-consuming procedure. This may further drive up the price of 3D printed medications and restrict patient access to them.

Market Trends of the Global 3D Printed Drugs Market

Pharmaceutical businesses working together with 3D printing companies: In the global market for 3D printed drugs, partnerships between pharmaceutical corporations and 3D printing companies are become more frequent. This partnership is spurring industry innovation and accelerating the release of novel medications and drug delivery technologies. To create innovative medications and drug delivery systems, pharmaceutical companies are collaborating with 3D printing businesses. The manufacture of intricate medication formulations and customized medications with exact dosage and customized formulas is made possible by 3D printing technology. Innovation in the global market for 3D printed drugs is being driven by partnerships between pharmaceutical companies and 3D printing enterprises. This partnership is accelerating the release of new medications and drug delivery technologies, and it is anticipated to sustain industry expansion in the years to come.

Positive government initiatives: The global market for 3D printed drugs is expanding thanks in large part to positive government initiatives. Globally, numerous governments are launching programs to encourage the advancement and application of 3D printing technology in the medical field. These programs are promoting market expansion and assisting in the development of a regulatory framework that is favorable to the sector. Positive government actions are a major factor in the global market for 3D printed drugs' expansion. These programs include fostering innovation, advancing the development of novel medications and drug delivery technologies, and assisting in the establishment of a regulatory environment that is favorable to the sector.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global 3D Printed Drugs Market by Technology Type

Market Overview
Inkjet Printing
Fused Deposition Modeling
Stereolithography
and Zip Dose Technology

Global 3D Printed Drugs Market by Application

Market Overview
Orthopaedic
Neurology
Dental
and Others

Global 3D Printed Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Aprecia Pharmaceuticals - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FabRx - (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline - (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi - (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
3D Systems - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BASF - (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceuticals - (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis - (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche - (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim - (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers - (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International - (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioBots - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apium Additive Technologies - (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boston Micro Fabrication - (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments